Pembrolizumab yemejwe mu Bushinwa ku ndwara ya HCC idakira ivanze na Lenvatinib na TACE

Mu minsi ishize, Merck & Co., Inc. (Merck) yatangaje ko umuti wayo wo gukumira PD-1, pembrolizumab, wemejwe n'Ikigo cy'Igihugu gishinzwe Ibikoresho by'Ubuvuzi (NMPA) cyo mu Bushinwa kugira ngo ukoreshwe hamwe na lenvatinib na transarterial chemoembolization (TACE) mu kuvura abarwayi ba kanseri y'umwijima idakira kandi idatera kanseri.

Kwemeza iki kimenyetso gishya bishingiye ku makuru yavuye mu igerageza rya LEAP-012 ry’icyiciro cya gatatu. Muri ubu bushakashatsi bw’icyiciro cya gatatu cy’ibizamini byinshi, byakozwe mu buryo bwa "randomized", budafite ubumuga bwo kubura amaso, bw’icyiciro cya gatatu (LEAP-012), abarwayi 480 biyandikishije kandi bashyirwa mu byiciro bitandukanye kugira ngo bahabwe lenvatinib hamwe na TACE hamwe na pembrolizumab (n=237) cyangwa TACE hamwe na dual placebo (n=243).

Ibisubizo byagaragaje ko ubwiyongere bw’ubuzima budafite progression (PFS) bwari amezi 14.6 mu itsinda rya lenvatinib hamwe na TACE hamwe na pembrolizumab, ugereranyije n’amezi 10.0 mu itsinda rya placebo. Igipimo cy’ubuzima rusange bw’amezi 24 (OS) cyari 75% na 69%.

Lenvatinibni umuti ubuza kinase ukoreshwa mu kuvura ubwoko bumwe na bumwe bwa kanseri. Ubibuza kinase ni imiti ibuza enzymes gukora kwa poroteyine kinase imwe cyangwa nyinshi.

Pembrolizumab ni antibody ya monoclonal IgG4 kappa yakozwe n’umuntu irwanya ubuso bw’uturemangingo tw’umubiri w’umuntu PD-1 (programmed death receptor-1) kuri lymphocytes. Receptor ya PD-1 itanga "ahantu ho kugenzura ubudahangarwa bw’umubiri" hakenewe, bigafasha gukumira ubudahangarwa bw’umubiri kwibasira. Hari ubwoko bumwe na bumwe bw’ibibyimba bufite imiterere myinshi ya PD-L1 (programmed death receptor ligand-1). Izindi ndwara zikoresha ubudahangarwa bw’umubiri aho zifata imiterere karemano ya PD-L1 (kurinda kwangirika kw’ubudahangarwa bw’umubiri ku ndwara) zikayihuza n’uburyo bwo kurwanya kanseri. Iyo PD-L1 ihuye na PD-1, imikorere ya T-cell irahagarara; pembrolizumab ibuza imiterere ya PD-1: PDL-1 ituma habaho kwica T-cells neza.

Kugeza ubu, haracyari igeragezwa ryinshi ry’ikoranabuhanga rishya rirwanya kanseri mu Bushinwa rishaka abarwayi. Inama ku miti mishya n’ikoranabuhanga, ushobora kuvugana n’Ishami Mpuzamahanga ry’Ibitaro bya Oncology bya Beijing mu Karere k’Amajyepfo.

Nimero ya Terefone: 4008803716

Email：myimmnet@163.com